171 related articles for article (PubMed ID: 30761387)
1. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.
Liu D; Takhar M; Alshalalfa M; Erho N; Shoag J; Jenkins RB; Karnes RJ; Ross AE; Schaeffer EM; Rubin MA; Trock B; Klein EA; Den RB; Tomlins SA; Spratt DE; Davicioni E; Sboner A; Barbieri CE
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30761387
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of the SPOP mutant genomic subclass in prostate cancer.
Shoag J; Liu D; Ma X; Oromendia C; Christos P; Ballman K; Angulo C; Cai PY; Gaffney C; Klein E; Karnes J; Den RB; Liu Y; Davicioni E; Barbieri CE
Urol Oncol; 2020 May; 38(5):418-422. PubMed ID: 32192889
[TBL] [Abstract][Full Text] [Related]
3. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
4. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
Liu D; Augello MA; Grbesa I; Prandi D; Liu Y; Shoag JE; Karnes RJ; Trock BJ; Klein EA; Den RB; Demichelis F; Davicioni E; Sboner A; Barbieri CE
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998599
[TBL] [Abstract][Full Text] [Related]
5. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
6. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis.
Pedrani M; Salfi G; Merler S; Testi I; Cani M; Turco F; Trevisi E; Tortola L; Treglia G; Di Tanna GL; Vogl U; Gillessen S; Theurillat JP; Pereira Mestre R
Eur Urol Oncol; 2024 May; ():. PubMed ID: 38704358
[TBL] [Abstract][Full Text] [Related]
8. Opposing Roles of
Cavalcante L; Deshmukh SK; Ribeiro JR; Carneiro BA; Dizon DS; Angara K; Mattox T; Wu S; Xiu J; Walker P; Oberley M; Nabhan C; Huang H; Antonarakis ES
JCO Precis Oncol; 2023 Sep; 7():e2300088. PubMed ID: 37677121
[TBL] [Abstract][Full Text] [Related]
9. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
10. Key pathways in prostate cancer with SPOP mutation identified by bioinformatic analysis.
Ding G; Sun J; Jiang L; Gao P; Zhou Q; Wang J; Tong S
Open Med (Wars); 2020; 15(1):1039-1047. PubMed ID: 33336059
[TBL] [Abstract][Full Text] [Related]
11. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and prognostic significance of speckle-type POZ protein in cancers: a systematic review and meta-analysis.
He Y; Chen J; Peng X; Xia Y; Su Y
Cancer Cell Int; 2021 Nov; 21(1):626. PubMed ID: 34838022
[TBL] [Abstract][Full Text] [Related]
13. The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis.
Ma J; Cai M; Mo Y; Fried JS; Tan X; Ma Y; Chen J; Han S; Xu B
Front Oncol; 2021; 11():658230. PubMed ID: 34322378
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer.
Zhou J; Lai Y; Peng S; Tang C; Chen Y; Li L; Huang H; Guo Z
Front Oncol; 2022; 12():957404. PubMed ID: 36119488
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
[TBL] [Abstract][Full Text] [Related]
16. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
[TBL] [Abstract][Full Text] [Related]
17. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
18. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Barbieri CE; Baca SC; Lawrence MS; Demichelis F; Blattner M; Theurillat JP; White TA; Stojanov P; Van Allen E; Stransky N; Nickerson E; Chae SS; Boysen G; Auclair D; Onofrio RC; Park K; Kitabayashi N; MacDonald TY; Sheikh K; Vuong T; Guiducci C; Cibulskis K; Sivachenko A; Carter SL; Saksena G; Voet D; Hussain WM; Ramos AH; Winckler W; Redman MC; Ardlie K; Tewari AK; Mosquera JM; Rupp N; Wild PJ; Moch H; Morrissey C; Nelson PS; Kantoff PW; Gabriel SB; Golub TR; Meyerson M; Lander ES; Getz G; Rubin MA; Garraway LA
Nat Genet; 2012 May; 44(6):685-9. PubMed ID: 22610119
[TBL] [Abstract][Full Text] [Related]
19. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.
Gao X; Mohideen N; Flanigan RC; Waters WB; Wojcik EM; Leman CR
J Urol; 2000 Dec; 164(6):1982-6. PubMed ID: 11061896
[TBL] [Abstract][Full Text] [Related]
20. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
